The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA 1 Safety in GCA patients was consistent with known safety profile of Cosentyx ® (secukinumab) 1 EAST HANOVER, N.J. , July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx ® (secukinumab) in adults with newly diagnosed or... Read More